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OBJECTIVES: To assess the predictive value (PV) of genetic testing for abacavir
hypersensitivity syndrome (HSR) in the Western Australian HIV Cohort Study, and to
extend genetic mapping of genetic susceptibility locus/loci. Abacavir-specific
immunological responseswere assessed to improve precision of the HSR diagnostic
classification, and to provide insights into possible underlying mechanisms.
METHODS: The abacavir-exposed cohort comprised prospectively tested patients (n=48)
and retrospectively analysed abacavir-exposed individuals (n=200). Diagnostic precision
was assessed using epicutaneous patch testing, and immunological response to ex vivo
abacavir exposure measured by peripheral blood mononuclear cell tumour necrosis factor
alpha (TNF-α ) expression (three-colour flow cytometry) or whole blood extracellular
TNF-α(chemiluminescence). Depletion of CD4 and CD8 cells was undertaken to
determine the characteristics of the major histocompatibility complex (MHC)-restricted
immune response. MHC typing utilized standard molecular techniques, and genetic
mapping within the MHC Class III region analysed single nucleotide polymorphisms
(SNP) to identify recombinant MHC haplotypes.
RESULTS: Application of revised diagnostic criteria (including a positive ex vivo test)
identified abacavir HSR 18 cases out of 248 abacavir-exposed patients (2/48
prospectively tested).HLA-B*5701was present in 94% of cases and 1.7% of controls(OR 587, PV+ 81%, PV– 99.6%). Based on these data, prospective testing for HLA-
B*5701carriage would be predicted to reduce abacavir HSR incidence from 7.3% to
0.4%, while inappropriately denying 1.6% of the population access to abacavir. Presence
ofHLA-B*5701and a central MHC polymorphism (hspA1L rs2227956C) was found in
94% of cases and 0.43% of controls (OR 3910, PV+ 94%, PV– 99.5%). Depletion of
CD8 cells resulted in marked attenuation of abacavir-stimulated TNF-αexpression ex
vivo, consistent with a Class I-restricted immune response. Recombinant mapping in
patients carrying markers of the 57.1 ancestral/extended haplotype suggest a
susceptibility locus within the highly conserved heat shock protein 70 (hsp70) gene
cluster, although these data suggest that the HLA-B*5701 may provide specificity to the
abacavir-induced immune response.
CONCLUSIONS: Presence of HLA-B*5701 is highly predictive of abacavir HSR in the
Western Australian HIV Cohort, with evidence that an abacavir-specific Class I-restricted
immune response may involve the concurrence of HLA-B*5701 and a second locus
within the central MHC that is carried on the 57.1 extended haplotype.
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